Back to top

crispr: Archive

Zacks Equity Research

CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates

CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.

ALKSNegative Net Change VRTXPositive Net Change CRSPNegative Net Change CSTLNegative Net Change